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ABSTRACT
Previous observations indicated that C3G (RAPGEF1) promotes α-granule release, 
evidenced by the increase in P-selectin exposure on the platelet surface following 
its activation. The goal of the present study is to further characterize the potential 
function of C3G as a modulator of the platelet releasate and its implication in the 
regulation of angiogenesis.
Proteomic analysis revealed a decreased secretion of anti-angiogenic factors from 
activated transgenic C3G and C3G∆Cat platelets. Accordingly, the secretome from both 
transgenic platelets had an overall pro-angiogenic effect as evidenced by an in vitro 
capillary-tube formation assay with HUVECs (human umbilical vein endothelial cells) 
and by two in vivo models of heterotopic tumor growth. In addition, transgenic C3G 
expression in platelets greatly increased mouse melanoma cells metastasis. Moreover, 
immunofluorescence microscopy showed that the pro-angiogenic factors VEGF and 
bFGF were partially retained into α-granules in thrombin- and ADP-activated mouse 
platelets from both, C3G and C3GΔCat transgenic mice. The observed interaction 
between C3G and Vesicle-associated membrane protein (Vamp)-7 could explain these 
results. Concomitantly, increased platelet spreading in both transgenic platelets upon 
thrombin activation supports this novel function of C3G in α-granule exocytosis. 
Collectively, our data point out to the co-existence of Rap1GEF-dependent and 
independent mechanisms mediating C3G effects on platelet secretion, which regulates 
pathological angiogenesis in tumors and other contexts. The results herein support 
an important role for platelet C3G in angiogenesis and metastasis.
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INTRODUCTION
C3G, also known as RAPGEF1, is a guanine 
nucleotide exchange factor (GEF) for Rap1 and R-Ras 
proteins that participates in numerous cellular processes 
such as proliferation, differentiation, migration, apoptosis 
and cell-cell contact maintenance [1–8]. C3G is a 
multidomain protein consisting of a N-Terminal domain, 
which interacts with E-cadherin, a central region with 
several polyproline tracts (SH3-binding domain) capable 
of interacting with proteins containing SH3 domains, 
and a carboxy-terminal region that includes the catalytic 
(REM-CDC25) domain, responsible for its GEF activity 
[6]. Many C3G functions are mediated by interaction 
with other proteins through its SH3-binding domain, 
independently of its catalytic (GEF) activity [1, 3–8]. 
Using transgenic mouse models expressing human 
full-length C3G or mutant C3G∆Cat (with a deletion in 
the catalytic domain), specifically in megakaryocytes 
and platelets, we previously showed that C3G increased 
platelet activation and aggregation, both in vitro and 
in vivo [9]. Specifically, C3G participates in platelet 
functions triggered by thrombin, ADP, PMA and collagen 
through the activation of its main effector Rap1b, which 
is known to play an important role in primary hemostasis 
by targeting αIIbβ3 integrin [10, 11]. In particular, we 
demonstrated that C3G mediates the activation of Rap1 
induced by thrombin and PMA via protein kinase C 
(PKC) [9].
In addition to their essential functions in hemostasis 
and thrombosis, platelets also play a role in the regulation of 
immune responses, cancer metastasis, vascular development 
and angiogenesis [12, 13]. Platelets are recruited to sites of 
vascular injury where they interact with the endothelium 
to regulate angiogenesis [14]. Platelets contribute to this 
process by providing both, pro-angiogenic factors and 
angiogenic inhibitors, which are localized in secretory 
α-granules [15]. There is controversy on how proteins with 
potentially antagonistic functions are packaged within 
α-granules. Some authors have described a differential 
segregation of pro-angiogenic and anti-angiogenic 
proteins into different sets of platelet α-granules, which are 
selectively released in response to distinct agonists [16, 17]. 
According to them, pro-angiogenic granules are released 
in response to ADP, PAR1 or GPVI, while secretion of 
anti-angiogenic proteins is triggered by PAR4 or TXA2 
activation [17, 18]. However, data from other authors 
suggest that protein delivery to individual granules, as well 
as platelet secretion, are stochastic processes and that pro- 
and anti-angiogenic α-granule proteins show low functional 
co-clustering [19, 20]. 
Some of the mechanisms that control platelet 
α-granule secretion have begun to be elucidated at the 
molecular level. Vesicular Soluble N-ethylmaleimide-
sensitive factor Attachment protein REceptors 
(v-SNAREs), present in α-granules, associate to target 
membrane SNAREs (t-SNAREs) to generate the energy 
required for membrane fusion [21, 22]. α-granules are 
heterogeneous in the content of v-SNAREs VAMPs 
isoforms, which correlates with functionally distinct 
α-granules subtypes. In spreading human platelets, only 
α-granules expressing VAMP-7 translocate to peripheral 
lamellipodia and pseudopodia, while granules containing 
VAMP-3 and VAMP-8 remain in the central granulomere 
[23]. This indicates the participation of VAMP-7, but 
not VAMP-3 or VAMP-8, in spreading. In addition to 
its SNARE domain, VAMP-7 contains an N-terminal, 
profilin-like longin domain that binds to G-actin and 
ARP2/3, suggesting its putative participation in actin 
remodeling [23, 24].  
Angiogenesis is critical to allow tumor growth and 
platelets play an important role in the regulation of tumor 
angiogenesis [25, 26]. Therefore, based on the previously 
identified function of C3G in platelet activation, we 
hypothesized that platelet C3G could regulate tumor 
growth by modulating angiogenesis.
In this paper we show that C3G regulates mouse 
platelet secretome. Specifically, C3G controls the secretion 
of pro- and anti-angiogenic factors from thrombin- or 
ADP-stimulated mouse platelets, which results in the 
modulation of angiogenesis, both in vivo and in vitro, 
including tumor angiogenesis and metastasis. In contrast 
to its role in platelet aggregation, the function of C3G in 
platelet secretion appears to be mainly independent of its 
GEF activity. The interaction between C3G and Vamp-7 
may explain, at least in part, this novel C3G function. 
RESULTS 
Release of anti-angiogenic factors is reduced 
in tgC3G and tgC3G∆Cat mouse platelets, 
following activation with thrombin or ADP
C3G overexpression in platelets increases P-selectin 
expression on the surface [9].  Since P-selectin is stored 
in α-granules, but it is present only in the membrane of 
activated platelets, we wanted to study whether C3G could 
regulate platelet activity by modulating the secretion of 
factors stored in its granules. To do this, we performed a 
proteomic analysis by LC-MS/MS using secretome from 
equal number of thrombin- or ADP-stimulated platelets 
of the different genotypes (tgC3G, tgC3G∆Cat and their 
respective wild types). The purity of the releasate fraction 
was confirmed by the absence of platelet membrane–
specific protein αIIb (Supplementary Figure 1). Table 1 
summarizes the 20 most abundant, differentially regulated, 
proteins released from thrombin- or ADP-activated mouse 
platelets. Remarkably, release of the anti-angiogenic 
factors thrombospondin-1 (TSP-1), platelet factor 4 
(PF4) and von Willebrand factor (vWF), all of them in 
the top 20, was diminished in tgC3G and tgC3GΔCat 
mouse platelets, following activation with thrombin. 
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Table 1: Top 20 most abundant proteins released from thrombin- or ADP-activated mouse platelets 
of each genotype
Top 20 proteins from thrombin-induced releasates 
Accession no. Protein identity MW [kDa]
#PSM
Ortholog
2C1- 2C1+ 8A3- 8A3+
P07724 Serum albumin 68.6 603 635 650 790 *     †
Q80YQ1 Thrombospondin-1 129.6 194 151 163 99 *     †
Q921I1 Serotransferrin 76.6 129 111 127 158 *     †
Q9Z126 Platelet factor 4 11.2 99 85 71 65 *     †
Q61838 Alpha-2-macroglobulin 165.7 68 41 67 89 *     †
Q00623 Apolipoprotein A-I 30.5 47 34 42 71 *     †
A8DUK4 Beta-globin 15.7 37 - 54 66 *     †
P60710 Actin, cytoplasmic 1 41.7 48 37 59 29 *     †
P63260 Actin, cytoplasmic 2 41.7 47 36 57 29 *     †
P26039 Talin-1 269.6 47 21 55 31 *     †
A0A0R4J0I1 MCG1051009 (Serpin3K) 46.6 24 20 54 56 ―
P01942 Hemoglobin subunit alpha 15.0 42 26 - 60 *     †
E9PV24 Fibrinogen alpha chain 87.3 39 18 31 - *     †
Q91X72 Hemopexin1 51.2 28 17 25 23 *     †
P21614 Vitamin D-binding protein 53.5 21 14 26 26 *     †
P01027 Complement C3 186.3 25 6 28 22 *
E9QPU1 von Willebrand factor 308.9 25 12 29 19 *     †
P20918 Plasminogen 90.7 22 2 30 22 *     †
P28665 Murinoglobulin-1 165.1 14 7 26 12 ―
Q00896 Alpha-1-antitrypsin 1-3 45.7 13 14 14 22 *     †
Top 20 proteins from ADP-induced releasates 
Accession no. Protein identity MW [kDa]
#PSM
Ortholog
2C1- 2C1+ 8A3- 8A3+
P07724 Serum albumin 68,6 501 684 616 685 *     †
Q921I1 Serotransferrin 76,7 110 117 115 120 *     †
Q61838 Alpha-2-macroglobulin 165,7 81 51 73 58 *     †
Q80YQ1 Thrombospondin 1 129,6 72 62 84 44 *     †
Q00623 Apolipoprotein A-I 30,6 29 30 47 66 *     †
P60710 Actin, cytoplasmic 1 41,7 48 24 45 29 *     †
A0A0R4J0I1 MCG1051009 46,6 43 20 43 39 ―
P63260 Actin, cytoplasmic 2 41,8 46 22 43 26 *     †
P26039 Talin-1 269,7 50 19 37 16 *     †
P01027 Complement C3 186,4 42 25 23 19 *
Q91X72 Hemopexin 51,3 41 24 23 15 *     †
P21614 Vitamin D-binding protein 53,6 33 26 22 19 *     †
Q8VDD5 Myosin-9 226,2 38 17 25 7 †
B7FAU9 Filamin, alpha 280,3 21 18 18 13 *     †
Q8K0E8 Fibrinogen beta chain 54,7 40 7 14 7 *     †
P20918 Plasminogen 90,7 30 10 16 11 *     †
Q00896 Alpha-1-antitrypsin 1-3 45,8 14 14 19 16 *     †
P28665 Murinoglobulin-1 165,2 24 7 17 13 ―
P17742 Peptidyl-prolyl cis-trans isomerase A 18,0 19 16 17 8 ―
Q9Z126 Platelet factor 4 11,2 12 10 21 17 *     †
 The amount of PSM (peptide-Spectrum Matches) was used as a quantitative measure of the relative abundance of each protein in the sample [51]. (*) Orthologs detected in 
human purified platelet releasates [56] or (†) releasates including platelet-derived microparticles [57]. (–) Indicate that the human ortholog has not been detected in platelet 
secretomes to date. 2C1-: wtC3G; 2C1+: tgC3G; 8A3-: wtC3G∆Cat; 8A3+: tgC3G∆Cat. 15 µl out of 200 µl of platelet secretome obtained from 3 mice of each genotype was 
used in the proteomic analysis.
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Similar results were found in the ADP-induced releasates, 
although in this case only TSP-1 and PF4 were among the 
top 20 (vWF: rank 36 in tgC3G, rank 52 in tgC3G∆Cat) 
(Table 1 and Supplementary Table 2). Additional data 
containing the top 100 differentially regulated proteins per 
treatment are displayed in Supplementary Tables 1 and 2. 
Apart from TSP-1, PF4 and vWF, the release of other 
anti-angiogenic factors, such as α-1-antitrypsin 1-5 and 
Metalloproteinase inhibitor 3, was reduced in thrombin-
activated tgC3G and tgC3G∆Cat platelets. In addition, 
α-2-macroglobulin secretion was also decreased in tgC3G 
platelets. Regarding secretomes from ADP-stimulated 
platelets, we found lower secretion of α-2-macroglobulin, 
α-1-antitrypsin 1-2, α-1-antitrypsin 1-4 and α-1-antitrypsin 
1-5 in both transgenics. 
Angiogenesis inhibitors and activators are 
differentially stored in resting mouse platelets
In human platelets, pro- and anti-angiogenic 
factors are segregated into distinct subpopulations 
of α-granules [16, 18]. This prompted us to analyze 
whether mouse platelets also showed a differential 
distribution of angiogenic regulators. We examined, by 
immunofluorescence confocal microscopy, the subcellular 
localization of two pro-angiogenic factors: VEGF and 
bFGF, and two anti-angiogenic factors: endostatin and 
TSP-1 in resting platelets, isolated from tgC3G and 
tgC3G∆Cat mice and their controls. As in the case of 
human platelets, most of the mouse platelet α-granules 
were stained for either VEGF (green) or endostatin (red), 
as indicated by the lack of colocalization (yellow) in the 
merged image (Supplementary Figure 2). Similar results 
were observed when comparing the localization of TSP-1 
and bFGF (Supplementary Figure 3). 
To our knowledge, this is the first report showing a 
differential localization of pro- and anti-angiogenic factors 
in mouse platelet α-granules.
C3G regulates the release of VEGF, bFGF, 
endostatin and TSP-1 from mouse platelets 
following activation with ADP or thrombin
Next, we tested whether there is a differential 
release of pro- and anti-angiogenic factors from mouse 
platelets activated with ADP or thrombin and whether 
C3G plays a role. ADP activation promoted the selective 
release of VEGF- (but not endostatin) containing 
α-granules from platelets of both control groups (Figure 
1A and 1C), in agreement to previous reports from human 
platelets [18, 27]. However, VEGF was mostly retained 
within tgC3G and, to a lesser extent, tgC3GΔCat mouse 
platelets, suggesting a role for C3G as an inhibitor of 
VEGF secretion (Figure 1A and 1C). Similar results 
were observed for bFGF, mainly in tgC3G platelets 
(Supplementary Figure 4). Likewise, we assayed the 
dynamics of granule release in transgenic mouse platelets 
activated with thrombin. In human platelets, thrombin 
activation through PAR4 promotes the differential 
release of endostatin versus VEGF [16]. A similar result 
was observed in platelets from our control mice (Figure 
1B and 1D). However, tgC3G platelets had a lower 
remaining content of endostatin following activation with 
thrombin, while tgC3GΔCat platelets seemed to have 
more remaining endostatin than the controls. In contrast, 
immunofluorescence analysis of TSP-1 suggests increased 
retention in tgC3G platelets upon thrombin stimulation 
(Figure 1E and 1F), in agreement with the proteomic data 
(Table 1). 
Interestingly, thrombin also increased the retention 
of VEGF and bFGF in both transgenic platelets, mainly 
in tgC3G (Figure 1E, 1G and Supplementary Figure 4). 
Images depicted in Supplementary Figures 2 and 3 are the 
unstimulated controls of those shown in Figures 1A, 1B 
and Figure 1E, respectively.
All these results suggest that C3G, through GEF- 
dependent and independent mechanisms, would play a role 
in mediating a selective release of some angiogenic factors 
from platelet α-granules in response to thrombin or ADP.  
Results from Figure 1 and Supplementary Figure 4 
suggested that in tgC3G platelets and, to a lesser extent, 
in tgC3G∆Cat platelets, C3G could be mediating the 
sequestration of VEGF- or bFGF-containing granules. 
Indeed, following ADP activation, C3G partially 
colocalized with VEGF, mainly in tgC3G platelets 
(Figure 2). This result supports a role for C3G as an 
inhibitor of VEGF release through interaction with VEGF-
containing α-granules. 
To further investigate whether C3G regulates VEGF 
release and the mechanisms involved, we analyzed the 
amount of protein remaining within the platelet upon 
stimulation with thrombin or ADP. Unexpectedly, a slight 
but clear decrease in VEGF was observed in clarified 
lysates from thrombin-stimulated tgC3G and tgC3G∆Cat 
platelets, compared to their controls (Figure 3A), 
suggesting the release of this factor from the transgenic 
platelets. However, the majority of VEGF was retained 
on the membrane fraction in both transgenic samples 
(Figure 3B). These results are in agreement with those 
from Figures 1 and 2 and support a role for C3G in the 
regulation of VEGF secretion. Likewise, the content of 
TSP-1 was lower in lysates from thrombin-stimulated 
tgC3G and tgC3G∆Cat platelets, compared to their 
controls (Figure 3A). In addition, this factor was also 
retained in the plasma membrane of platelets from all 
genotypes. However, the total amount of TSP-1 (cytosolic 
content plus membrane content) was lower in the two 
transgenic samples (Figure 3B), in agreement to the lower 
secretion detected by proteomics and immunofluorescence. 
No detectable changes were observed in lysates from 
ADP-stimulated platelets, probably due to the weakness 
of this agonist (Figure 3A). 
Oncotarget110998www.impactjournals.com/oncotarget
Releasates from tgC3G and tgC3G∆Cat 
thrombin- or ADP-activated platelets promote 
angiogenesis in vitro 
To investigate the physiological significance of our 
findings, we studied the ability of platelet releasates from 
the different mouse genotypes to promote angiogenesis. 
To do it, we monitored the formation of capillary tubes in 
HUVEC exposed to the secretome from platelets stimulated 
with thrombin or ADP. We quantified 3 parameters: number 
of junctions, length of master segments, and mesh size to 
accurately measure capillary formation, as described [28]. 
Releasates from thrombin-activated transgenic platelets 
promoted the formation of capillary networks with greater 
number of junctions, mean length of master segments, and 
mean mesh size, in comparison with platelets from wild-
type mice (being significant, at least, two parameters) 
(Figure 4A). Similarly, endothelial cells exposed to the 
secretome from tgC3G and tgC3G∆Cat platelets treated 
with ADP, showed a significant increase in the formation 
of capillary networks (Figure 4B). In this case, only the 
number of junctions in the tgC3G∆Cat and the mean mesh 
size in the tgC3G reached a significant value, probably 
due to the weakness of this agonist (less induction of 
protein release), as compared to thrombin, in agreement 
with observations by other authors [29]. Overall, these 
results support the idea of a putative pro-angiogenic role 
of platelet C3G in response to thrombin and ADP, and are 
in agreement with the reduced secretion of anti-angiogenic 
factors detected in both transgenic secretomes in the 
proteomic analysis. No differences in cell proliferation 
between HUVECs treated with the different secretomes 
were observed (data not shown). 
Platelet C3G regulates in vivo angiogenesis 
Platelets cooperate with tumor cells to induce new 
blood vessels growth. Specifically, tumor cells stimulate 
the selective release of pro-angiogenic proteins from 
platelets [18, 30]. Based on that, we analyzed whether 
Figure 1: C3G regulates the release of VEGF, bFGF, endostatin and TSP-1 from ADP- and thrombin-stimulated 
platelets. Double immunofluorescence confocal microscopy images showing the subcellular distribution of VEGF (left), endostatin 
(middle) and an overlay (right) in three representative ADP-activated mouse platelets (A) or thrombin-activated mouse platelets (B) from 
each genotype. Platelets were activated for 5 min under stirring conditions. All micrographs were taken at the same exposure time. Scale 
bars: 0.4 µm. The graphs show arbitrary values of immunofluorescence intensity (mean ± SEM) for VEGF (C) or endostatin (D) in the 
ADP- or thrombin-treated platelets respectively. (E) Representative confocal microscopy images of the subcellular distribution of TSP-1 
and bFGF in thrombin-activated platelets of the indicated genotypes. All micrographs were taken at the same exposure time. Scale bars: 
0.4 µm. The graphs show arbitrary values of immunofluorescence intensity (mean ± SEM) for TSP-1 (F) or bFGF (G) in each genotype. 
*p < 0.05; **p < 0.01.
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Figure 2: C3G interacts with VEGF in ADP-stimulated platelets from tgC3G mice. (A) Double immunofluorescence confocal 
microscopy images showing the subcellular distribution of VEGF (left), C3G (middle) and an overlay (right) in three representative ADP-
stimulated mouse platelets from each group. C3G was detected with rabbit anti-C3G antiserum #1008 [33]. All micrographs were taken at 
the same exposure time. Scale bars: 0.4 µm. (B) The graph shows the Manders´correlation coefficients (mean ± SEM) of the colocalization 
between VEGF and C3G. **p < 0.01.
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platelet C3G regulates the generation of new blood 
vessels in two models of syngeneic heterotopic tumor 
cells transplantation: murine Lewis lung carcinoma 
(3LL) cells and B16-F10 mouse melanoma cells. 3LL-
induced tumors presented a higher size accompanied 
by a higher cell death extension in both transgenic mice 
(Figure 5A and 5B). These results are indicative of a 
higher tumorigenic capacity of 3LL cells in mice with 
circulating tgC3G and tgC3G∆Cat platelets, probably as a 
consequence of their higher angiogenic potential. Indeed, 
tumors grown in both transgenic mice showed increased 
vascularization, as assessed by CD31 staining. TgC3G 
presented a higher number of vessels, while tgC3G∆Cat 
had larger vessels than controls (Figure 5C, 5D and 
5E). In concordance, we also found a significant higher 
tumor growth of B16 melanoma cells in tgC3G mice, as 
compared to their control littermates (Figure 5F). This 
correlated with a more extensive vascularization (Figure 
5G, 5H and Supplementary Figure 5). In addition, tumors 
developed in tgC3G mice showed a more intense staining 
for P-selectin, indicating increased platelet activation 
(Supplementary Figure 5). B16-F10 cells did not grow 
in tgC3G∆Cat mice, probably due to differences in their 
genetic backgrounds. Collectively, these results indicate 
that C3G-regulated platelet secretome favors in vivo 
tumor angiogenesis.
To confirm this in vivo pro-angiogenic effect 
of platelet C3G, angiogenesis was evaluated in a 
model of oxazolone-induced ear inflammation. No 
differences in inflammation, measured as ear lobe size, 
were observed between the different genotypes (data 
not shown). However, histochemical analysis showed 
a significantly higher number of blood vessels in the 
ears from tgC3G mice (Supplementary Figure 6A and 
6B), while tgC3G∆Cat mice showed larger vessels 
than their controls (Supplementary Figure 6A and 6C). 
These results agree with those observed in the tumor 
angiogenesis model.
Figure 3: Release of VEGF is impaired in tgC3G and tgC3G∆Cat platelets. (A) Western blot analysis of VEGF and TSP-1 in 
cell lysates from mouse platelets of the indicated genotypes (4 mice per group) in resting condition or stimulated with thrombin or ADP. 
Anti-β-actin (AC-15) and anti-β-tubulin (2-28-33) antibodies from Sigma-Aldrich were used as loading controls. Relative VEGF/β-actin 
or TSP-1/tubulin ratios are shown. All values are relative to the corresponding wild-type controls. (B) Western blot analysis of VEGF and 
TSP-1 in platelet membranes corresponding to equal amounts of lysed platelets following thrombin activation. 2C1: tgC3G line; 8A3: 
tgC3G∆Cat line. The total content of TSP-1 (cytoplasm plus membrane) was quantified in thrombin-stimulated platelets of the different 
genotypes. Values are relative to the corresponding wild-type controls. Cyto: cytoplasm, mbm: membrane.
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To further characterize the role of platelet C3G in in 
vivo angiogenesis, we evaluated the infiltration of CD31 
positive endothelial cells into Matrigel plugs containing 
bFGF. Only tgC3G∆Cat platelets showed a tendency 
to induce a greater neovascularization within Matrigel 
than their controls (data close to statistical significance) 
(Supplementary Figure 7). These results are not in 
contradiction with those observed in tumor angiogenesis, 
taking into account that the mechanisms that operate in both 
contexts are not comparable. In agreement, no differences 
in angiogenesis were observed in bFGF-Matrigel plugs 
implanted in TSP-1 knockout mice versus wild types, 
despite the strong anti-angiogenic potential of TSP-1 [31]. 
Platelet C3G promotes melanoma metastasis
The above results indicate that platelet C3G may 
support tumor cell growth by favoring tumor angiogenesis. 
Platelets interact with tumor cells to facilitate their 
metastatic potential in vivo [30, 32]. In addition, platelets 
protects metastatic tumor cells from the immune system 
during their transit through the circulation and helps tumor 
cells to attach to the endothelium at metastatic sites [13].
To investigate whether transgenic expression of 
C3G in platelets influences the metastatic potential of 
B16-F10 melanoma cells, we intravenously injected 2.5 
x 105 B16-F10 melanoma cells into tgC3G mice and their 
Figure 4: Releasate from thrombin- or ADP-activated transgenic platelets promotes higher formation of capillary 
networks in HUVECs. Representative images showing the capillary-like structures formed by HUVECs seeded onto basement 
membrane matrix and supplemented with each of the indicated releasates from thrombin- (A) or ADP- (B) stimulated platelets (2:30 hours 
post-releasate supplementation). Scale bars: 100 μm.  Graphics show the mean values of different network characteristics determined and 
averaged from 2 to 5 hours. Master segments consist on pieces of tree delimited by two junctions, none exclusively implicated with one 
branch (master junctions). Data is presented as the mean ± SEM of 3 independent experiments per quadruplicate. *p < 0.05.
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controls. The average number of metastases in the lungs 
of tgC3G mice was 61 ± 16.1, whereas the average for 
the controls was 15.5 ± 7.33 (n = 4 mice in both groups, 
p = 0.042) (Figure 6A and 6B). In addition, histological 
examination of lung sections revealed a significant 
difference in the number of tumor foci per section in the 
two experimental groups (Figure 6C and 6D). Lungs from 
tgC3G mice showed an average of 10 ± 1.12 metastatic 
foci, while lungs from wild type animals showed 
2.17 ± 0.56 foci (n = 12 sections analyzed per group, 
 p = 0.0000028).
 C3G interacts with Vamp-7 in transgenic mouse 
platelets 
It has been described that VEGF is located in 
VAMP-7 (also known as TI-VAMP)-containing α-granules 
[23]. VAMP-7 is a v-SNARE protein required for normal 
a-granule exocytosis [24]. We hypothesize that C3G 
could retain VEGF by interacting with VAMP-7. To 
analyze this, we looked for the presence of Vamp-7 in 
C3G immunoprecipitates from tgC3G and tgC3G∆Cat 
platelet lysates. Results in Figure 7A support an 
interaction between Vamp-7 and C3G in both resting and 
thrombin-activated platelets. This interaction was also 
detected in a C3G-overexpressing K562 cell line, where 
the C3G-VAMP-7 association was dependent on PMA, a 
stimulator of megakaryopoiesis in these cells (Figure 7B). 
The interaction between C3G and VAMP-7 was further 
supported by co-immunoprecipitation assays in lysates 
from HEK293T cells co-transfected with CFP-VAMP-7, 
together with HA-tagged C3G or pLTR2C3G∆Cat [33] 
constructs. Both, the longin and the SNARE domains of 
VAMP-7 seem to contribute to its association with C3G 
Figure 5: Platelet C3G regulates in vivo angiogenesis: Heterotopic tumors display enhanced growth in transgenic mice. 
(A) Cell death extension in tumors originated by subcutaneous injection of Lewis lung carcinoma cells in wtC3G, tgC3G, wtC3GΔCat, 
and tgC3GΔCat mice. Representative light microscopy images of tumor slices stained with hematoxylin/eosin showing cell death area 
(*). (B) Quantification of cell death extension is expressed as the percentage of the total tumor area that is occupied by dead cells. The 
histograms represent the mean value ± SEM (n = 4 for wtC3G and tgC3G; n = 3 for wtC3GΔCat and tgC3GΔCat). Scale bars: 2.5 mm. 
(C) Representative images of 3LL tumor sections, from the indicated genotypes, showing vessel density by CD31 staining. Scale bars: 
20 µm. Quantification of vessel number (D) and vessel size (E) in tumor sections from the indicated genotypes. 3 representative areas per 
tumor were analyzed. (F to H) B16-F10 melanoma tumors developed in tgC3G mice have a greater mass and are more vascularized than 
tumors developed in wtC3G mice. (F) Quantification of tumoral mass (n = 7 for tgC3G, n = 8 for wtC3G). (G) Quantification of vessels in 
3 representative areas per tumor. All values correspond to the mean ± SEM. (H) Representative images of B16-F10 tumor sections showing 
immunoreactivity for CD31. Presence of vessels is indicated with asterisks. Scale bars: 20 µm. Inset, image enlargement showing a blood 
vessel, indicated by an arrowhead, stained for CD31 with the Chromo Map kit + Purple. *p < 0.05; **p < 0.01; ***p < 0.001.   
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and C3G∆Cat (Figure 7C and 7D). Thus, this interplay 
between C3G and Vamp-7 might be the mechanism 
responsible for the retention of these cargos inside the 
platelet following its activation. The fact that Vamp-7 also 
interacts with C3G∆Cat provides a potential explanation 
of how both intact C3G and catalytically inactive C3G 
affect granule release.
Platelet spreading is increased in tgC3G and 
tgC3G∆Cat mouse platelets
Vamp-7 plays a role in the spreading of mouse 
platelets through its interaction with Varp (VPS9-domain 
ankyrin repeat protein) and Arp2/3 [24]. Upon activation, 
Vamp-7-expressing granules are recruited to platelet 
periphery where they fuse with the plasma membrane, 
thus contributing to membrane extension during the 
spreading [23]. We studied the capacity of tgC3G, 
tgC3G∆Cat and their control platelets to spread on poly-
L-lysine upon thrombin stimulation. Spreading, measured 
as surface area, was significantly increased in both 
transgenic platelets as compared to that of control platelets 
(Figure 8A). To link this observation with a functional 
association between C3G and Vamp-7, we studied their 
immunocolocalization in spread platelets. Figure 8B 
shows that C3G colocalized with Vamp-7, mainly in 
the transgenic platelets, in correlation with the observed 
increase in spreading (Manders coefficients [M1]: 0.56  ± 
0.07 for wtC3G; 0.73 ± 0.09 for tgC3G; 0.65 ± 0.03 for 
wtC3G∆Cat and 0.73 ± 0.12 for tgC3G∆Cat platelets). 
Localization of Vamp-7 in the periphery of platelets is 
an indicator of the proper functioning of the spreading 
stimulus. No significant colocalization was observed in 
non-stimulated platelets (data not shown).
These results indicate that C3G plays a role in 
platelet spreading acting through a GEF independent 
Figure 6: Platelet C3G favors melanoma metastasis. TgC3G and wtC3G mice were injected with melanoma B16-F10 cells. Lungs 
were removed 15 days after tumor cell injection, and surface metastases were quantitated. (A) Macroscopic pictures (three representative 
examples from each of the groups) showing a clear increase in the number of metastatic foci in tgC3G lungs, as compared to lungs from 
control mice. (B) Surface metastases per lung were counted in both groups. The graph shows the average number of metastases in each 
group (n = 4 mice per genotype). *p < 0.05. (C) Representative lung sections of two mice from each genotype, showing hematoxylin/eosin 
staining. Arrows point to metastatic foci in the lung sections. Scale bars: 10 µm. (D) Values in the graph represent the number of tumor foci 
per area (n = 12 lung sections per group analyzed). P-value comparing the groups is shown.
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mechanism and suggest that the interaction between C3G 
and Vamp-7 increases the capacity of Vamp-7-containing 
vesicles to fuse with the plasma membrane. 
DISCUSSION 
In this study we demonstrate for the first time that 
transgenic C3G and C3G∆Cat expression modifies platelet 
α-granule secretion, which leads to changes in the release 
of angiogenic regulators. As previously observed in human 
platelets, angiogenic and anti-angiogenic factors are also 
organized into separate α-granules in mouse platelets 
[16]. Furthermore, like in human platelets, in wild type 
mouse platelets ADP induces the release of the angiogenic 
factors VEGF and bFGF, while thrombin triggers the 
release of anti-angiogenic factors, such as endostatin and 
TSP-1 [16, 17]. However, transgenic expression of C3G 
and mutant C3G∆Cat alters this pattern. Both transgenes 
caused VEGF and bFGF retention in platelet membranes 
upon thrombin stimulation, although tgC3G colocalized 
to a greater extent with both pro-angiogenic proteins. In 
addition, both transgenes provoked a reduction in the 
release of several anti-angiogenic factors from ADP- or 
thrombin-stimulated platelets. 
In mouse platelets, not only ADP-, but also 
thrombin-stimulated platelet secretomes have a net pro-
angiogenic effect in vitro, promoting capillary formation. 
This is in agreement with results from human platelets, 
where thrombin induces the secretion of VEGF and 
endostatin (through PAR1 and PAR4 respectively), but 
the global balance is pro-angiogenic in an in vitro model 
[18, 34]. The greater pro-angiogenic effect of the releasates 
from tgC3G and tgC3G∆Cat platelets, despite VEGF is 
retained within their α-granules, is in agreement with a 
non-essential role of VEGF, in in vitro angiogenesis [34]. 
The diminished secretion of anti-angiogenic factors from 
Figure 7:  C3G interacts with Vamp-7 in platelets from tgC3G and tgC3G∆Cat mice. (A) Immunoprecipitation of C3G 
from resting (Rest) and thrombin (TH, at 0.2 U/mL) stimulated platelets for 5 min at 37ºC under stirring. Vamp-7 in the immunocomplexes 
was detected by Western blot with anti-TI-VAMP antibody (Santa Cruz Biotechnologies, sc-67060). Platelet cell lysate from 4 mice of 
each genotype was used. b: lysate incubated with agarose beads. (B) Immunoprecipitation of C3G from stably C3G-overexpressing K562 
cells untreated (basal) or treated with 20 nM PMA for 10 min. C3G and VAMP-7 in the immunocomplexes were detected with anti-TI-
VAMP and anti-C3G antibodies. L: total cell lysate (50 µg). b: lysate incubated with agarose beads. (C) HEK293T cells were transiently 
transfected with a HA-tagged C3G construct together with the indicated CFP-VAMP-7 fusion proteins or the empty pCDNA3-CFP-C4 
plasmid (CFP). Ectopic C3G was immunoprecipitated with anti-HA.11 monoclonal antibody and C3G and VAMP-7 detected with anti-C3G 
and anti-TI-VAMP (arrows). b: agarose beads incubated with non-transfected lysate. L: total cell lysate (50 µg). IP: immunoprecipitated 
with anti-HA.11. (D) HEK293T cells were transiently transfected with pLTR2C3G∆Cat construct or the empty pLTR2 vector [33], together 
with the above CFP-VAMP-7 constructs. C3G was immunoprecipitated with anti-C3G antibodies (IP) and C3G and VAMP-7 detected with 
anti-C3G and anti-GFP (Santa Cruz Biotechnologies, sc-9996) antibodies. L: total cell lysate. VAMP7-NT: N-terminal (longin) domain 
of VAMP-7 (aminoacids 1-120); VAMP7-CT: C-terminal (SNARE) domain of VAMP-7 (aminoacids 121-188); VAMP7-cyto: VAMP-7 
cytosolic domain (aminoacids 1-188).
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both transgenic platelets, mainly TSP-1, likely accounts 
for their increased net pro-angiogenic potential. 
This novel function of C3G as a regulator of 
angiogenesis was confirmed by in vivo analyses using 
two syngeneic heterotopic cancer models, where a 
significant pro-angiogenic effect of platelet C3G was 
found. The higher levels of angiogenesis observed 
in tumors developed in tgC3G and tgC3G∆Cat mice 
correlates with the lower TSP-1 content in the secretomes 
from these two genotypes. This is in agreement with the 
negative role played by platelet TSP-1 in tumorigenesis 
[12, 35]. 
A similar tendency was observed in the Matrigel 
plug assay, but only in tgC3G∆Cat mice. This seemingly 
discrepancy points to a complex regulatory role for platelet 
C3G in angiogenesis, beyond granule secretion, which 
probably involves the participation of cellular interactions 
between platelets and the surrounding environment. 
It is worth mentioning that although tgC3G 
and tgC3G∆Cat platelets behave similarly in most 
experimental approaches, they show divergences that may 
account for the differences observed in the in vivo Matrigel 
assay. Thus, while tgC3G platelets retain more VEGF 
and bFGF within their α-granules, in response to ADP or 
thrombin, they also release more endostatin than the other 
genotypes. Accordingly, elevated levels of endostatin have 
been linked to various pathological conditions [36]. On the 
other hand, several reports have documented the important 
role of the proteolytic activity of the plasminogen (plg) 
system in Matrigel-induced angiogenesis; e.g. explants of 
plg-/- mice cultured in Matrigel showed a complete lack 
of angiogenesis [37, 38]. Plasminogen levels were much 
lower in the thrombin-induced secretome from tgC3G 
platelets (Table 1), which may explain the poor angiogenic 
response of these mice to Matrigel plugs. In contrast, 
thrombin-induced tgC3G∆Cat secretome presents levels of 
Figure 8: TgC3G and tgC3GΔCat platelets present higher areas of spreading following activation with thrombin, 
in correlation with higher levels of C3G-Vamp-7 colocalization. (A) Representative confocal microscopy images of platelet 
spreading on poly-L-lysine-coated glass coverslips upon stimulation with thrombin. Scale bars: 5 μm. The graphs show the mean ± SEM 
of the spreading area normalized to that of wild-type platelets. *p < 0.05. An average of 48 platelets from each genotype was measured. (B) 
Representative double immunofluorescence confocal microscopy images of granules in spread platelets stained with antibodies to C3G 
(rabbit antiserum #1008 [33]) and VAMP-7 (anti-SYBL1, Abcam, ab36195). Scale bars: 2 µm. The graph shows the Manders´correlation 
coefficients (mean ± SEM) of the colocalization between C3G and Vamp-7. *p < 0.05.  TgC3G 6A6 line was used.
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plasminogen close to control ones. This fact, together with 
a greater decrease in anti-angiogenic factors, may explain 
the increased angiogenesis observed in the Matrigel plugs 
of tgC3G∆Cat mice. In addition, circulating platelets have 
been described to uptake and store proteins that regulate 
angiogenesis [12, 25] including VEGF from Matrigel 
plugs [39]. Subsequently, other mechanisms, such as the 
uptake of the bFGF from the Matrigel by tgC3G platelets 
can not be excluded. 
Several studies using in vitro and in vivo models, have 
demonstrated a correlation between the potential of tumor 
cells to induce platelet aggregation and the contribution of 
platelets to tumor metastasis [13, 40, 41]. In this regard, 
the increase in the number of metastasis observed in tgC3G 
mice, as compared to their controls, is in agreement with 
our previous work showing a greater platelet activation and 
aggregation, both in vitro and in vivo, in this genotype [9].
Altogether these results indicate that platelet C3G 
regulates the release of angiogenic factors through GEF-
dependent and independent mechanisms, in contrast 
to its role in the activation of integrin αIIbβ3 that is 
mediated by Rap1b [9]. Accordingly, it has been described 
that secretion of VEGF and endostatin may occur 
independently of the platelet aggregation response [34]. 
In addition, α-granule secretion, but neither dense granule 
secretion nor platelet aggregation, is involved in platelet-
induced angiogenesis [12].
Our data also unveil a novel interaction between 
C3G, VEGF and Vamp-7, which could explain the 
inhibitory role of C3G in the release of VEGF. As VEGF 
is stored in Vamp-7-containing granules and its secretion 
is dependent on Vamp-7-mediated exocytosis [23], we 
reasoned that C3G could prevent VEGF secretion by 
interacting with Vamp-7. Indeed, C3G colocalizes with 
VEGF and forms complexes with Vamp-7 in platelets. 
This interaction was also observed in a K562 cell line 
over-expressing C3G, which induces megakaryocytic 
features (unpublished results from our group). Varp, a 
GEF for Rab21 involved in vesicle transport, regulates 
the exocytosis of platelet α-granules by interacting with 
Vamp-7 and ARP2/3 [24]. Similarly to Varp, C3G interacts 
with both the longin and the SNARE domains of Vamp-
7 [42]. Varp inhibits α-granule fusion with the plasma 
membrane, by preventing SNARE complex formation 
[24, 43]. Upon activation Varp is released from Vamp-7, 
which can now interact with t-SNAREs [24]. In contrast, 
the interaction between C3G and Vamp-7 increases after 
stimulation, indicating a positive role of C3G in Vamp-
7 function. In concordance, transgenic platelets showed 
higher spreading, suggesting that C3G-Vamp-7 interaction 
promotes α-granule fusion with the plasma membrane. 
However, this fusion is not sufficient for the release of 
VEGF, which rather remains on the plasma membrane. 
Additional studies should be conducted to determine the 
mechanism by which VEGF and, presumably bFGF, are 
being retained by C3G and whether Vamp-7 collaborates. 
In neuritogenesis, Vamp-7/Arp2/3 complex participates in 
exocytosis and actin dynamics through an integrin-FAK-
Src-dependent pathway [44]. Participation of C3G in focal 
adhesion complexes and actin cytoskeleton remodeling 
has been extensively described [3, 6, 7, 45, 46], and 
supports a role for C3G in Vamp-7-mediated cytoskeletal 
regulation and membrane delivery.
It should be highlighted that a distinctive feature 
of C3G, as compared with other GEFs, is its ability to 
perform a number of functions independently of its Rap1 
activating domain. Using our mouse models (tgC3G and 
tgC3GΔCat) we herein demonstrate that C3G-mediated 
α-granule release and hence, its role in platelet-mediated 
angiogenesis are mainly independent of Rap1 functions. 
In contrast, as previously demonstrated, the role of C3G 
in platelet aggregation is Rap1-dependent [9]. Moreover, 
although the results shown here are derived from the 
analysis of the effect of a transgenic C3G and C3G∆Cat 
expression, endogenous expression of C3G has been 
detected in both human and mouse platelets by several 
authors, using genomic and proteomic approaches 
[47–49]. This is in agreement with a relevant role of 
C3G in platelets. In addition, we have preliminary 
data showing that C3G silencing or knock-out in K562 
and HEL erythroid cells prevents the acquisition of 
megakaryoycytic features (unpublished results). 
In summary, we have described a novel function of 
C3G in platelet-mediated angiogenesis in tumors and other 
contexts, through the modulation of α-granule secretion, 
likely by its interaction with Vamp-7. Furthermore, 
our data suggest that decreased secretion of TSP-1 is 
probably the most important event that contributes to the 
tumorigenesis mediated by platelet C3G. Although our 
proteomic analysis does not show a differential secretion 
of major pro-tumorigenic growth factors or inflammatory 
molecules from the transgenic platelets, we can not 
exclude the possibility that factors, other than angiogenic, 
may play a role. In addition, we showed a novel role of 
C3G in platelet-dependent tumor cell metastasis. This 
points out to a putative prognostic use of platelet C3G 
in cardiovascular disease and cancer progression. Future 
studies should aim at addressing whether platelet C3G 
may play a role in angiogenesis-related disorders and 
cancer metastasis, which may be of value in designing 
novel therapeutic approaches.
MATERIALS AND METHODS 
Animal models
Transgenic mice used in this work have been 
previously described [9]. C3G (full-length) and 
C3G∆Cat (deleted in the catalytic region) transgenes 
from human origin are expressed under the control of 
the megakaryocyte and platelet specific PF4 promoter. 
Transgenic C3G (tgC3G) lines 2C1 and 6A6 were used. 
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2C1 was generally used, unless otherwise indicated. For 
transgenic C3G∆Cat (tgC3G∆Cat), 8A3 line was used. 
Platelet activation and isolation of platelet 
releasate
Platelets from 6 mice of the same genotype were 
pooled and suspended in modified Tyrode´s buffer (130 
mM NaCl, 10 mM trisodium citrate, 9 mM NaHCO3, 
6 mM dextrose, 0.9 mM MgCl2, 0.81 mM KH2PO4, 10 
mM Tris pH 7.4) at 2 × 108 platelets/mL, as described 
[9]. Platelets were supplemented with 2 mM CaCl2 and 
activated under stirring conditions (1100 rpm) with 0.2 U/
mL thrombin or 25 mM ADP for 5 min at 37ºC. Following 
aggregation, platelets were removed by centrifuging twice 
at 2500g for 10 min at 4ºC and the supernatant harvested. 
LC-MS/MS Analysis and Database Search
Sample proteins were digested using standard methods 
and analyzed by LC-MS/MS using a LTQ-Velos-Orbitrap 
mass spectrometer (Thermo Fisher Scientific) coupled to a 
nano-UPLC system (nanoAcquity, Waters Corp.). 
MASCOT search algorithm was used for searching 
the acquired MS/MS spectra, using Thermo Scientific 
Proteome Discoverer software (v. 1.4.1.14) against a 
custom database of mouse proteome AUP000000589 
downloaded from UniProt on December 2015, and Mann 
database of common contaminant sequences. One percent 
false discovery rate (1% FDR) using Percolator was used 
for peptide validation [50]. Only proteins with 2 or more 
peptides were considered. The sum of PSMs (Peptide-
Spectrum Matches) was used as a quantitative measure of 
the abundance of each protein [51].
Immunofluorescence microscopy 
Platelets from 3 mice were pooled and activated 
as indicated above. Platelets were fixed for 15 minutes 
by adding 1 vol of 4% formaldehyde, placed onto poly-
L-lysine-coated coverslips and allowed to settle for 50 
minutes. Attached platelets were permeabilized with 
0.5% Triton X100 and blocked overnight in PBS with 1% 
BSA. Incubation with primary antibodies: VEGF (Abcam, 
ab1316), bFGF (Abcam ab8880), endostatin (Thermo 
Scientific, PA1-601), TSP-1 (Thermo Scientific MA5-
13398), C3G (#1008 [33]), and VAMP-7 (anti-SYBL1, 
Abcam, ab36195), was performed at RT for 2h, followed 
by incubation (1 h at RT) with secondary antibodies: Cy3-
conjugated Goat anti-rabbit (Abcam) for bFGF, endostatin 
and C3G; Cy5-conjugated Goat anti-mouse (Jackson 
Immunoresearch) for VEGF, TSP-1 and VAMP-7.
Immunofluorescence was quantified with ImageJ 
software. Colocalization was determined by Manders 
coefficient (M) analysis, using ImageJ with the JACoP 
plugin, as described [23, 52].
Capillary tube formation assay
HUVEC (human umbilical vein endothelial cells) 
were cultured in EBM medium (Lonza) according to their 
protocol. Cells were diluted 1:5 in PBS and 32,000 cells (in 
37.5 µl volume), mixed with 15 µl of platelet releasate (out 
of 200 µl, the amount obtained from 3 animals), diluted to 
37.5 µl in PBS. The mix (75 µl) was immediately plated 
onto Matrigel matrix in 96 well plates. Capillary tube 
formation was allowed to develop at 37ºC, 5% CO2, and 
recorded every hour using a Zeiss Axiovert 135 microscope. 
Angiogenic capacity was determined by quantifying 3 
parameters: number of junctions, length of master segments, 
and mesh size. Data were collected each hour from 2 to 
6 hours and represented as the average number of each 
parameter during the entire experimental time course. 
Heterotopic syngeneic transplantation 
A suspension of 106 3LL (murine Lewis lung carcinoma) 
cells or 3.3x105 B16-F10 mouse melanoma cells, diluted in 
100 µl of PBS, was injected in the shaved flanks of mice. The 
size of the tumors was measured with a caliper on alternate 
days and their weight quantified at the time of extraction (day 
11 for 3LL tumors, day 15 for B16 tumors). Extracted tumors 
were fixed in 4% formaldehyde and embedded in paraffin 
for their histological analysis. The percentage of apoptotic 
or necrotic cells on tumor sections stained with hematoxylin/
eosin was determined using ImageJ software. 
In vivo angiogenesis model by oxazolone 
induction
Mice were pre-sensibilized by subcutaneous injection 
of a 2% oxazolone (Sigma) solution, prepared in acetone/
corn oil (4:1). After six days, contact hypersensitivity was 
induced by the topical application of a 1% oxazolone 
solution in one of the mouse ears. The animals were 
sacrificed 48 h later and treated ears were dissected, fixed in 
4% paraformaldehyde and embedded in paraffin. Sections 
of tissue were stained with hematoxylin/eosin.
Experimental pulmonary metastasis
B16-F10 mouse melanoma cells (2.5 × 105 in 100 µl 
PBS per mouse) were injected through the lateral tail vein, 
as previously described [32]. After 15 days, lungs were 
removed, rinsed with PBS and the numbers of surface 
metastases were counted. The pulmonary lobes were fixed 
in 4% paraformaldehyde, embedded in paraffin and stained 
using hematoxylin/eosin for their histological analysis.
Immunohistochemistry
Paraffin embedded sections from 3LL and B16-F10 
tumors were used to detect CD31 (Abcam, ab28364), and 
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P-selectin (Santa Cruz Biotechnology, sc-6941) using 
Ventana Discovery platform (Roche). P-selectin was 
developed with Chromo Map Kit (Roche) and CD31 
with Chromo Map kit (3LL) or Chromo Map kit + Purple 
(B16-F10). Stained areas were scanned and quantified 
using ImageJ software. 
Western blot and immunoprecipitation
For Western blot platelets were lysed in RIPA 
Modified Buffer (100 mM Tris pH 7.5, 400 mM NaCl, 
5 mM MgCl2, 2% Igepal, 20% Glycerol, 1mM PMSF) 
supplemented with manufacturer recommended amount 
of cOmpleteTM Protease Inhibitor Cocktail (Roche). After 
centrifugation, membrane fraction was directly suspended 
in loading buffer 1X.
For immunoprecipitation, platelets and 
cell lines were lysed in standard RIPA buffer [3]. 
Immunocomplexes were pulldown with anti-C3G (Santa 
Cruz Biotechnologies, sc-15359) or anti-HA.11 (Covance) 
antibodies and purified with protein G agarose resin 4 
rapid run (ABT).
VAMP-7 and C3G constructs 
Human VAMP-7 longin (aa 1-120), SNARE (aa 121-
188) and full cytosolic (aa 1-188) domains were amplified 
from pEGFP-VAMP7 (1-220), a gift from Thierry 
Galli (Addgene plasmid #42316) [53] and cloned into 
pcDNA3-CFP-C4 (a gift from Dr. J.M Pereda, IBMCC, 
Salamanca, Spain) as CFP-fusion proteins, with CFP in 





GTGATG-3´ and hVAMP7-R188-XbaI: 5´-GCGGCC 
GCTCTAGACTACTTGAGGTTCTTCATACACATG-3´, 
based on [43]. An expression vector derived from pCEFL-
HA [54], containing HA-tagged full human C3G (with HA 
in the N-terminus) was a gift from Dr. J.M. Pereda. 
Platelet spreading 
Platelets isolated from 4 mice per genotype and 
suspended in 500 µL of modified Tyrode´s buffer were 
activated with 0.2 U/mL thrombin. 150 µL of the suspension 
was immediately applied onto 12-mm glass coverslips 
precoated with poly-L-lysine. Platelets were allowed to 
adhere and spread for 30 min at 37ºC. Unbound platelets 
were removed by aspiration, followed by fixation using 
4% paraformaldehyde. Platelets were further processed for 
immunofluorescence as described above. For visualization 
of actin structures, Oregon Green® 514 Phalloidin (Thermo 
Fisher Scientific) was used. ImageJ software was used to 
determine the surface area of spread platelets. 
Matrigel plug angiogenesis assay
The Matrigel plug assay was performed as described 
[55]. The method is detailed in the Supplemental Methods.
Statistical analysis
Normality of the data sets was verified using the 
Kolmogorov-Smirnov test. Homogeneity of the variances 
was verified by the Levene test. Statistical analysis was 
performed using an unpaired Student’s t-test. Data are 
represented as mean ± SEM. Results were considered 
significant when p < 0.05.
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